Current controversies in prenatal diagnosis 1: Should NIPT routinely include microdeletions/microduplications?

Prenatal Diagnosis

Volumn 36, Issue 1, 2016, Pages 10-14

  Rose, Nancy C ^a,b   Benn, Peter ^c   Milunsky, Aubrey ^d,e  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d Center for Human Genetic Research   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; DNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME DUPLICATION; CLINICAL ASSESSMENT; COPY NUMBER VARIATION; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOWN SYNDROME; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FAMILY HISTORY; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INTELLECTUAL IMPAIRMENT; MICRODELETION SYNDROME; MICRODUPLICATION SYNDROME; NONINVASIVE PRENATAL TESTING; PHENOTYPE; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CONFLICT; CONGENITAL ABNORMALITIES; FEMALE; GENETICS; MATERNAL SERUM SCREENING TEST; PREGNANCY; PROCEDURES;

BIOMARKERS; CHROMOSOME ABERRATIONS; CONGENITAL ABNORMALITIES; DISSENT AND DISPUTES; DNA; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MATERNAL SERUM SCREENING TESTS; PREGNANCY;

EID: 84956650516     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4710     Document Type: Article

References (36)

1. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
2. Chiu RWK, Akolekar R, Zheng YWL, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401.
3. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205.e1-11.
4. Sparks AB, Wang ET, Strube CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32(1):3-9.
5. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
6. Palomaki GE, Deciu C, Kloza KM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305.
7. Chen EZ, Chiu RWK, Sun H, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One 2011;6(7):e21791.
8. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901.
9. Wapner RJ, Martin CL, Levy B, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012;367(23):2175-84.
10. Wapner RJ, Babiarz JE, Levy B, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol 2015;212(3):332.e1-9.
11. McDonald-McGinn DM, Emanuel BS, Zackai EH. 22q11.2 Deletion Syndrome. In GeneReviews® [Internet], Pagon RA, Adam MP, Ardinger HH, et al. (eds.). Seattle (WA): University of Washington, Seattle; 1993-2015. 1999. [Accessed 7/23/2015].
12. Grati FR, Gomes DM, Ferreira JCPB, et al. Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn n.d;35(8):801-9.
13. Kambin, S. 22qOdyssyDimple. 2014. https://vimeo.com/99288218 [Accessed 7/23/2015].
14. Cheung EN, George SR, Andrade DM, et al. Neonatal hypocalcemia, neonatal seizures, and intellectual disability in 22q11.2 deletion syndrome. Genet Med 2014;16(1):40-4.
15. Wald NJ, Cuckle H, Brock JH, et al. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977;1(8026):1323-32.
16. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297(6653):883-7.
17. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17(9):821-9.
18. Canick JA, Palomaki GE, Osathanondh R. Prenatal screening for trisomy 18 in the second trimester. Prenat Diagn 1990;10(8):546-8.
19. Srinivasan A, Bianchi DW, Huang H, et al. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. Am J Hum Genet 2013;92(2):167-76.
20. Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin Chem 2015;61(4):608-16.
21. Helgson J, Wardrop J, Boomer T, et al. Clinical outcome of subchromosomal events detected by whole-genome noninvasive prenatal testing. Prenat Diagn 2015;35:999-1004, DOI: 10.1002/pd.4640.
22. Gross S, Stosic M, Norvez, et al. Clinical experience with an SNP-based noninvasive prenatal test for 22q11.2 deletion syndrome. Ultrasound Obstet Gynecol 2015, DOI:10.1002/uog.15754. [epub ahead of print].
23. Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2015;35(8):725-34.
24. Milunsky A, Littlefield JW, Kanfer JN, et al. Prenatal genetic diagnosis. N Engl J Med Part 1 1970; 283: 1370-81 Part 2. 1970;283:1441-1447. Part 3. 1970;283:1498-1504.
25. Milunsky A. The Prenatal Diagnosis of Hereditary Disorders. Charles C. Thomas: Springfield, Illinois; 1973.
26. Bianchi DW, Parsa S, Bhatt S, et al. Fetal sex chromosome testing by maternal plasma DNA sequencing. Obstet Gynecol 2015;125(2):375-82.
27. Wang J-C, Sahoo T, Schonberg S, et al. Discordant noninvasive prenatal testing and cytogenetic results: a study of 109 consecutive cases. Genet Med 2015;17(3):234-6.
28. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 2015;314(2):162-9.
29. McDonald-McGinn DM, Zackai EH. Genetic counseling for the 22q11.2 deletion. Dev Disabil Res Rev 2008;14(1):69-74.
30. McDonald-McGinn DM, Tonnesen MK, Laufer-Cahana A, et al. Phenotype of the 22q11.2 deletion in individuals identified through an affected relative: cast a wide FISHing net!. Genet Med 2001;3(1):23-9.
31. Gerdes M, Solot C, Wang PP, et al. Cognitive and behavior profile of preschool children with chromosome 22q11.2 deletion. Am J Med Genet 1999;85:127-33.
32. Bassett AS, Chow EWC, Husted J, et al. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Genet A 2005;138(4):307-13.
33. Ryan AK, Goodship JA, Wilson DI, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 1997;34(10):798-804.
34. Cohen E, Chow EWC, Weksberg R, et al. Phenotype of adults with the 22q11 deletion syndrome: a review. Am J Med Genet 1999;86(4):359-65.
35. Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol 2010;22:128-34.
36. Dondorp W, de Wert G, Bombard Y. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015;1-13, DOI: 10.1038/ejhg.2015.57. [Epub ahead of print]